clinical trial · NCT06874335
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Biohaven Therapeutics Ltd.·phase1·recruiting·n = 95
Solid TumorBHV-1530
brief summary
This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
started
Mar 20, 2025
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
May 13, 2026
official title
A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Confirmation Study of BHV-1530 in Adult Patients With Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol